selleck kinase inhibitor None of the participants dropped out during the 3-year study period. Table 1 Descriptive statistics of sickness absence parameters Total (N = 244) Men (N = 103) Women (N = 141) N Mean SD Median N Mean SD Median N Mean SD Median Total episodes 1,085 4.4 3.8 4 350 3.4 2.8 3 735 5.2 4.2 5 Short (1–21 days)episodes 991 4.1 3.5 3 327 3.2 2.7 2 664 4.7 3.9 4 Long (>21 days) episodes 94 0.4 0.7 0 23 0.2 0.5 0 71 0.5 0.8 0 Sick days during study (from 2002 to 2004) 11,940 48.9 82.8 18 3,304 32.3 62.2 12 8,636 61.1 93.4 26 Earlier sick days (in 2000 and 2001) 4,566 18.7 51.3 3 976 9.4 32.6 3 3,590 25.4 60.7 4 SD standard deviation, PF-01367338 in vitro SE standard error of mean Psychosocial work conditions and sickness absence days Men had lower scores on repetitive
work than women as shown in Table 2, with P < 0.01 using the Mann–Whitney U test. Table 2 Associations between psychosocial work conditions and the number of sickness absence days Psychosocial work condition (Reference)
Total (N = 244) Men (N = 103) Women (N = 141) Mean (SD) b (SE) Mean (SD) b (SE) mean (SD) b (SE) Gender −0.44 (0.21)* Age 39.0 (8.9) 0.01 (0.01) 40.3 (8.9) 0.00 (0.02) 38.0 (8.8) 0.02 (0.02) Work pace (42) 41 (15) 0.03 (0.08) 42 (12) 0.20 (0.14) CYTH4 41 (16) −0.05 (0.10) Emotional demands (25) 27 (12) 0.05 (0.10) 27 (11) 0.06 (0.16) 27 (13) 0.05 (0.13) Psychological workload (74) 76 (16) 0.04 (0.08) 75 (15) −0.07 (0.12) 77 (17) 0.08 (0.10) Repetitive work (44) 43 (21) 0.08 (0.08) 37 (20) 0.02 (0.11) 48 (20) 0.10 (0.11) Educational opportunities (53) 51 (20) −0.05 (0.07) 49 (19) −0.10 (0.12) 52 (21) −0.04 (0.10) Job autonomy (39)a 41 (20) −0.02 (0.06) 35 (17) −0.01 (0.11) 45 (21) −0.06 (0.08) Decision authority (52)a 46 (19) 0.18 (0.08)* 41 (20) 0.26 (0.13)# 49 (17) 0.17 (0.12) Supervisor support (22)a 19 (13) 0.02 (0.10) 19 (12) 0.09 (0.17) 18 (15) 0.06 (0.13) Co-worker support (21)a 21 (11) 0.22 (0.10)* 22 (11) 0.16 (0.17) 21 (12) 0.22 (0.14) Role clarity (34) 28 (15) −0.17 (0.08)* 29 (14) −0.07 (0.13) 27 (15) −0.25 (0.11)* Role Lazertinib cost conflict (20) 17 (11) −0.05 (0.11) 17 (11) 0.02 (0.16) 17 (11) −0.09 (0.15) Job insecurity (46) 28 (31) 0.00 (0.04) 27 (30) −0.11 (0.06)# 23 ± 28 0.06 (0.05) R 2 0.124 0.141 0.